Trial Profile
Efficacy and Safety of Combination of Sorafenib as Preoperative Adjuvant and Latter Radiofrequency Ablation in the Treatment Of Recurrent Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms ESCALATOR
- 04 May 2017 Status changed from not yet recruiting to recruiting.
- 03 Apr 2017 New trial record